Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here's Why [Yahoo! Finance]
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 [Yahoo! Finance]
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? [Yahoo! Finance]